Australian Court Orders Biota Dispute With GSK To Mediation (Australia)
This article was originally published in PharmAsia News
An Australian judge ordered Biota Holdings to mediation in its dispute with GlaxoSmithKline over the marketing of the flu drug Relenza (zanamivir). Biota accused GSK in a court suit of not properly promoting the drug Biota developed and GSK licensed. The judge ordered mediation to be completed by May 16, 2008. Biota sued GSK in Australia for as much as $606 million, U.S., noting the drug's sales were overshadowed by Roche Holding's Tamiflu. (Click here for more
You may also be interested in...
PERTH, Australia - Biota Holdings' lawsuit with GlaxoSmithKline over antiviral influenza vaccine Relenza (zanamivir) is getting closer to resolution, the Melbourne, Australia-based biotech told PharmAsia News
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.